Breast Cancer Studies Currently Recruiting Participants at the University of Chicago Comprehensive Cancer Center

Study Number Title
Select
13073B A Multi-Modality Surveillance Program for Women At High Risk for Breast Cancer
9127 Improved MRi Images of Breast Lesions (not all cancer patients)
Select
09-151-B A Pilot Study of Chemoprevention of Green Tea in Women with Ductal Carcinoma in Situ
15837A A Long Term Investigation of Curative Treatment in Breast Cancer Patients
10-136-A The Correlation of Radiographic Complete Response on Breast MRI with Pathologic Complete Response in Patients Receiving Neoadjuvant Systemic Treatment
Select
10-183-B Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2 (ISPY 2 Trial)
11365B Computer-Aided Diagnosis of Breast Lesions in Mammograms
Select
10-487-A The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
Select
11-0173 S1007:A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
Select
11-0574 Pilot study to analyze a novel mechanism underlying response to tamoxifen therapy in breast cancer patients
12-1229 Contralateral Prophylactic Mastectomy in Women Diagnosed with Ipsilateral Breast Cancer
12-1467 A Pilot Study Evaluating the Effects of Bariatric Surgery on Biomarkers of Breast Cancer Risk
12-2052 Improved Management of High Risk Breast Lesions with Quantitative MRI
Select
13-0311 A Phase Ib Multi-Cohort Study of MK-3475 in Subjects with Advanced Solid Tumors
Select
13-0418 S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and Her2/Neu Negative Breast Cancer e3 Breast Cancer Study ¿ Evaluation Everolimus with Endocrine Therapy
Select
IRB13-0775 Validation of a Polygenic Neurotoxicity Risk Score in Patients with Unusually Severe Paclitaxel-Induced Neuropathy
Select
IRB13-0947 A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer That Is Estrogen or Progesterone Receptor-Positive and HER2-Normal
Select
IRB13-1122 A Phase 2 Clinical Trial Assessing the Correlation of Early Chanages in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2- Positive Breast Cancer
Select
IRB13-1000 Carboplatin, Gemcitabine, and Mifepristone for Advanced Breast Cancer and Recurrent or Persistent Epithelial Ovarian Cancer
Select
IRB13-1194 A Randomized Double-Blind, Placebo-Controlled Study of LEE011 in Combination with Letrozole for the Treatment of Postmenopausal Women with Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer who Received No Prior Therapy for Advanced Disease
Select
IRB13-1193 A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The ¿METRIC¿ Study)
IRB13-1337 Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
Select
IRB13-1365 A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Select
IRB13-1389 Phase I Study of Mifepristone in Combination with Eribulin in Patients with Locally Advanced/Metastatic Breast Cancer with a Dose Expansion Cohort in Patients with Triple Negative Breast Cancer
Select
IRB14-0283 A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Previously Treated Advanced or Metastatic HER2-negative Breast Cancer
IRB14-0461 Development of High Spectral and Spatial Resolution (HiSS) MRI for Measurement of Breast Density
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB14-0194 A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Select
CIRB14-0810 NSABP-B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.